Consensus Augmedix, Inc.

Equities

AUGX

US05105P1075

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
2.71 ^USD	-4.24%		-4.58%	-53.68%

Apr. 24	Augmedix Launches Industry's First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments	CI
Apr. 12	Augmedix Insider Sold Shares Worth $369,285, According to a Recent SEC Filing	MT

Evolution of the average Target Price on Augmedix, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c7b38100779183f8aa9a324e26e9f6c5.Hzdprdq14ILZ3fTww5_iEun-aFgXZsBFr99Gcuz9OaI.TmJfnrmY0syN5J-AqvPTSp6fWDoiU4p89pYVC7ana81JewraoPjU8JqRlw~1f94c624934ad75c1a8cbaa87c5bba29

Analyst Recommendations on Augmedix, Inc.

Augmedix Insider Sold Shares Worth $369,285, According to a Recent SEC Filing	Apr. 12	MT
Augmedix Insider Sold Shares Worth $454,454, According to a Recent SEC Filing	Apr. 05	MT
Augmedix Insider Sold Shares Worth $380,108, According to a Recent SEC Filing	Apr. 04	MT
Evercore ISI Adjusts Price Target on Augmedix to $4.50 From $6.50, Maintains In-Line Rating	Mar. 19	MT
Evercore ISI Initiates Augmedix With In Line Rating, Price Target is $6	Dec. 15	MT
Waning Optimism on Rate Hike Pause, Cisco Fall Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday	Nov. 16	MT
B. Riley Lifts Augmedix's PT to $7.50 From $6.50, Raises 2023 Outlook, Notes Increased Confidence in Business Trajectory; Maintains Buy Rating	Nov. 07	MT
B. Riley Lifts Augmedix's PT to $6.50 From $5.50 on Raised 2023 Outlook, Increased Confidence in Business Trajectory; Keeps Buy Rating	23-08-08	MT
B. Riley Lifts Augmedix's Price Target to $5.50 From $5 After Q1 Topline Beat, 'Strong' Q2 Guide; Keeps Buy Rating	23-05-15	MT
Benchmark Adjusts Price Target on Augmedix to $6 From $5, Maintains Buy Rating	23-04-21	MT
Maxim Group Adjusts Price Target on Augmedix to $8 From $5, Maintains Buy Rating	23-04-21	MT
B. Riley Lifts Augmedix's Price Target to $5 From $4 on Heels of Announced HCA Healthcare Partnership, Strategic Investment; Keeps Buy Rating	23-04-21	MT
Maxim Adjusts Price Target on Augmedix to $5 From $4, Maintains Buy Rating	23-03-28	MT
B. Riley Resumes Augmedix at Buy With $4 Price Target	22-12-29	MT
B. Riley Lowers Augmedix's Price Target to $4.50 from $6.50 Based on Lower 2023 Enterprise Value/Sales Multiple, Keeps Buy Rating	22-08-01	MT
Lake Street Initiates Augmedix at Buy with $6 Price Target	22-03-07	MT
Maxim Starts Augmedix at Buy with $6 Price Target	22-01-21	MT
Maxim Starts Augmedix at Buy With $6 Price Target	22-01-21	MT
William Blair Initiates Coverage on Augmedix With Outperform Rating	21-11-01	MT
Benchmark Starts Augmedix at Buy With $6 Price Target	21-11-01	MT
B. Riley Resumes Augmedix at Buy with $6.50 PT, Says Recent Capital Raise/Uplisting to Nasdaq Supports Growth Strategy Execution	21-10-29	MT